All In Biotech

Drug Trial Radar · NCT01032629

CANVAS - CANagliflozin cardioVascular Assessment Study

A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of JNJ-28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Dec 7, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 4,330 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,330

Actual

Start

Dec 9, 2009

Primary completion

Feb 22, 2017

Study completion Feb 22, 2017

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
Collaborators
The George Institute for Global Health, Australia
First posted
Dec 15, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will assess canagliflozin (JNJ-28431754) in the treatment of patients with type 2 diabetes mellitus (T2DM) with regard to cardiovascular (CV) risk for major adverse cardiac events (MACE). Other objectives include evaluating the overall safety, tolerability, and effectiveness of canagliflozin. The data from this study will be combined with the data from CANVAS-R study (Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects with T2DM, NCT01989754) in a pre-specified integrated analysis of CV safety outcomes to satisfy US FDA post-marketing requirements for canagliflozin.

Conditions

  • Diabetes Mellitus, Type 2
  • Cardiovascular Diseases
  • Risk Factors

Interventions

  • PlaceboDrug

    One placebo capsule taken orally (by mouth) once daily

  • Canagliflozin (JNJ-28431754) 100 mgDrug

    One 100 mg capsule taken orally (by mouth) once daily

  • Canagliflozin (JNJ-28431754) 300 mgDrug

    One 300 mg capsule taken orally (by mouth) once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Major Adverse Cardiovascular Events (MACE) Composite of Cardiovascular (CV) Death, Non-Fatal Myocardial Infarction (MI), and Non-Fatal StrokeTime frame: Up to approximately 8 years

Locations

305 sites in 25 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Mesa, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    La Mesa, California

  • Site not named

    Los Gatos, California

  • Site not named

    Pismo Beach, California

  • Site not named

    Stockton, California

  • Site not named

    Walnut Creek, California

  • Site not named

    Doral, Florida

  • Site not named

    Fort Lauderdale, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Plantation, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Duluth, Georgia

  • Site not named

    Boise, Idaho

  • Site not named

    Eagle, Idaho

  • Site not named

    Meridian, Idaho

  • Site not named

    Peoria, Illinois

  • Site not named

    Topeka, Kansas

  • Site not named

    Crestview Hills, Kentucky

  • Site not named

    Lexington, Kentucky

  • Site not named

    Auburn, Maine

  • Site not named

    Scarborough, Maine

  • Site not named

    Oxon Hill, Maryland

  • Site not named

    Royal Oak, Michigan

  • Site not named

    Kansas City, Missouri

  • Site not named

    St Louis, Missouri

  • Site not named

    Omaha, Nebraska

  • Site not named

    Camden, New Jersey

  • Site not named

    Flushing, New York

  • Site not named

    The Bronx, New York

  • Site not named

    Chapel Hill, North Carolina

  • Site not named

    Charlotte, North Carolina

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Cleveland, Ohio

  • Site not named

    Columbus, Ohio

  • Site not named

    Gallipolis, Ohio

  • Site not named

    Mentor, Ohio

  • Site not named

    Toledo, Ohio

Showing 40 of 305 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.